Squamous cell carcinoma of the lung chemotherapy
|
Squamous Cell Carcinoma of the Lung Microchapters |
|
Differentiating Squamous Cell Carcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Squamous cell carcinoma of the lung chemotherapy On the Web |
|
American Roentgen Ray Society Images of Squamous cell carcinoma of the lung chemotherapy |
|
Squamous cell carcinoma of the lung chemotherapy in the news |
|
Directions to Hospitals Treating Squamous cell carcinoma of the lung |
|
Risk calculators and risk factors for Squamous cell carcinoma of the lung chemotherapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2] Maria Fernanda Villarreal, M.D. [3]
Overview
Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with squamous cell carcinoma of the lung. Chemotherapy may be required upon histological subtype of squamous cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for squamous cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.
Chemotherapy
- Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging.
- Chemotherapy for patients with squamous cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation)
- Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with squamous cell carcinoma of the lung
- Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
- Chemotherapy treatments for squamous cell carcinoma of the lung, include:[1][2]
- Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung
- Platinum-based chemotherapy consists of four to six cycles
- Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent
- To see more information about mangnagment approach for non-small cell lung cancer click here
- To see more information about the chemotherapeutic regimens in non-small cell lung cancer click here
Complications
- Medical therapy complications for squamous cell carcinoma of the lung will depend on the chemotherapeutic agent.
- Common chemotherapy complications, include:[1]
- Platinum-based chemotherapy, the main dose-limiting side effect of cancer treatment with platinum compounds, include:
- Other chemotherapeutic agent complications, include:
- Side effects symptoms of chemotherapeutic agents, include:
References
- ↑ 1.0 1.1 Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899
- ↑ Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330